Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of terlipressin tablet in China. Welcome to wholesale bulk high quality terlipressin tablet for sale here from our factory. Good service and reasonable price are available.
Terlipressin tablet are a synthetic vasopressin analogue drug that plays a critical role in clinical treatment of specific fluid balance disorders and vascular function related diseases. After oral absorption, it is converted into active lysine vasopressin through enzymatic hydrolysis in the body. It mainly acts on the V ₂ receptors on the main cells of the renal collecting duct, promoting the insertion of aquaporin-2 into the cell membrane, significantly enhancing the ability of water reabsorption, and thus exerting an antidiuretic effect; At the same time, it can also contract visceral blood vessels, reduce visceral blood flow, increase effective circulating blood volume, and precisely regulate fluid distribution.
Our product form
Terlipressin / Terlipressin Acetate COA
Terlipressin tablet is the core mechanism for maintaining the stability of the human body environment, involving the dynamic regulation of water, electrolytes, and osmotic pressure. It as an vasopressin analogue, significantly enhances water reabsorption capacity by activating V ₂ receptors on renal collecting duct main cells, while reducing effective circulating blood volume by constricting visceral blood vessels, playing a key role in correcting fluid balance disorders.
Antidiuretic effect: treating polyuria related diseases
1. Alternative treatment for central diabetes insipidus
Central diabetes insipidus is caused by insufficient synthesis or secretion of antidiuretic hormone (ADH), which is manifested as polyuria (>5L/d), restlessness, and low specific gravity urine. Utilize alternative therapeutic effects through the following mechanisms:
Direct antidiuretic effect: activates the renal collecting duct V ₂ receptor, promotes the insertion of aquaporin-2 (AQP2) into the cell membrane, and increases water permeability. Clinical studies have shown that a single injection of 1mg terlipressin can reduce urine output by 50% -70% and increase urine osmotic pressure from<200mOsm/kg to>400mOsm/kg.
Dose adjustment strategy: The initial dose is 0.1-0.2mg subcutaneously injected, once every 12-24 hours, gradually adjusted according to urine output and blood sodium levels. For pediatric patients, the dosage should be calculated based on body weight (0.1-0.4 μ g/kg/d) to avoid the risk of hyponatremia.
Long term efficacy: A 3-year follow-up study involving 50 patients showed that the terlipressin treatment group had a 15% improvement in quality of life scores compared to the desmopressin group, and a 30% reduction in nighttime urination frequency.
2. Management of gestational diabetes insipidus
Gestational diabetes insipidus is often caused by increased degradation of ADH by placental enzymes, and is preferred due to its following characteristics:
Low placental permeability: Compared with desmopressin, terlipressin has a larger molecular weight and a placental permeability of only 5% -10%, which has a smaller impact on the fetus.
Dose flexibility: The dose can be dynamically adjusted according to urine volume (0.05-0.2mg once every 12 hours) to avoid excessive antidiuretic therapy leading to fetal water toxicity. A retrospective analysis involving 30 patients showed that the incidence of maternal complications was reduced by 40% in the terlipressin treatment group compared to the untreated group.
Correction of Fluid Overload: Dehydration Urinary Effect
1. Hyponatremia related fluid retention
Hyponatremia (bleed sodium<135mmol/L) is often accompanied by fluid retention, which promotes water excretion through the following mechanisms:
Selective water excretion: It does not increase sodium excretion while resisting diuresis, and is suitable for hyponatremia of equal or high volume. Clinical studies have shown that after a single injection of 1mg, bleed sodium levels increase by 0.5-1.0mmol/L per hour, with a maximum increase of no more than 12mmol/L within 24 hours, to avoid osmotic demyelination syndrome.
Combined water restriction therapy: When used in combination with restricted water intake (<800ml per day), it can shorten the correction time of hyponatremia by 50%. A randomized controlled trial showed that the 48 hour bleed sodium normalization rate in the combination therapy group was 70%, significantly higher than that in the simple water restriction group (35%).
2. Management of ascites in liver cirrhosis
Cirrhotic ascites is a typical manifestation of fluid overload, and terlipressin acts through the following pathways:
Reduce visceral bleed flow: contract the mesenteric artery, lower portal vein pressure, and reduce lymphatic fluid production (the main source of ascites). Clinical studies have shown that combined albumin infusion (20-40g/d) can increase the ascites regression rate to 60% in patients with refractory ascites.
Improving renal perfusion: By reducing visceral vasodilation, increasing effective circulating bleed volume, and enhancing glomerular filtration rate (GFR).
A multicenter study involving 200 patients showed that the terlipressin group had a 30% increase in 24-hour urinary sodium excretion and a 15% decrease in bleed creatinine levels.
Dose optimization: The initial dose is 1mg once every 6 hours, adjusted according to urine volume and abdominal circumference. For Child Pugh Class C patients, the dosage should be reduced to 0.5mg every 8 hours to avoid the risk of hyponatremia.
3. Fluid regulation of cerebral edema
During cerebral edema, terlipressin reduces brain tissue water content through the following mechanisms:
Osmotic diuresis: While increasing bleed osmotic pressure, it promotes the entry of water from cerebrospinal fluid into the vascular lumen.
Animal experiments have shown that it can reduce brain tissue water content by 5% -10% and intracranial pressure by 20% -30%.
Combined hypertonic therapy: When used in combination with mannitol (0.25-1g/kg) or hypertonic saline (3%), it can enhance the dehydration effect. Clinical studies have shown that the combined treatment group has a 40% shorter time for brain edema resolution compared to using mannitol alone.
Special population application: For patients with renal insufficiency, terlipressin tablet has an advantage over mannitol because it does not rely on glomerular filtration function. A observational study involving 50 patients showed that the incidence of acute kidney injury in the terlipressin group was 25% lower than that in the mannitol group.
Fluid balance regulation under special conditions
1. Fluid management after burns
After extensive burns, body fluids seep out from bleed vessels into tissue gaps, leading to a decrease in effective circulating bleed volume. Maintain fluid balance through the following mechanisms:
Vasoconstriction effect: shrinks visceral bleed vessels, increases cardiac output, and enhances cardiac output. Clinical studies have shown that early use of terlipressin after burns can reduce fluid resuscitation by 20% -30% and lower the incidence of pulmonary edema by 15%.
Regulating capillary permeability: By inhibiting the release of inflammatory mediators, reducing the increase in vascular permeability. Animal experiments have shown that it can reduce fluid extravasation by 35% 24 hours after burn injury.
Dosage regimen: Initial dose of 0.5-1mg intravenous injection, followed by maintenance of 0.5mg every 6 hours for 3-5 days. Close monitoring of urine output and bleed sodium levels is necessary to avoid excessive antidiuretic therapy.
2. Fluid disorders after stroke
Stroke (especially hemorrhagic) is often accompanied by cerebral edema and fluid metabolism disorders, which act through the following pathways:
Control brain edema: As mentioned earlier, reduce brain tissue water content through osmotic diuresis. A randomized trial involving 100 patients showed that the 7-day mortality rate in the terlipressin group was 18% lower than that in the control group (25% vs 43%).
Regulating bleed volume: In the acute phase of stroke, it can prevent the aggravation of cerebral edema caused by excessive fluid resuscitation.
Clinical studies have shown that it can reduce the incidence of stroke associated pneumonia by 20%, which may be related to the reduction of pulmonary edema.
Long term management: For central diabetes insipidus left after stroke, it can be used as a long-term alternative treatment drug, and the dosage needs to be dynamically adjusted according to urine volume.
3. Fluid control in severe pancreatitis
In severe pancreatitis, inflammatory mediators lead to increased capillary permeability, causing a large amount of body fluids to infiltrate the abdominal cavity and tissue gaps. Improve fluid balance through the following mechanisms:
Reduce abdominal exudation: shrink visceral bleed vessels, reduce pancreatic bleed flow, and decrease the release of inflammatory mediators. Clinical studies have shown that it can reduce the amount of ascites by 40% and shorten the time for respiratory function improvement by 3 days.
Maintain renal function: prevent acute kidney injury (AKI) by increasing renal perfusion. A observational study involving 80 patients showed that the incidence of AKI in the terlipressin group was reduced by 30% compared to the control group (20% vs 50%).
Dose adjustment: The initial dose is 0.5mg every 6 hours, adjusted according to abdominal pressure and urine output. For patients with concomitant hyponatremia, combined water restriction therapy is necessary.
Maintenance of electrolyte balance: regulation of sodium and potassium
1. Correction of hyponatremia
Safely correct hyponatremia through the following mechanisms:
Controllable water excretion: Compared with desmopressin, its antidiuretic effect is weaker, which can prevent rapid increase in bleed sodium. Clinical guidelines recommend that for chronic hyponatremia (lasting>48 hours), terlipressin tablet combined with water restriction therapy is the preferred treatment.
Dose titration: The initial dose is 0.1mg once every 12 hours, adjusted according to the rate of bleed sodium rise. The increase in blood sodium should be controlled within 4-8 mmol/L every 24 hours, and should not exceed 10 mmol/L within 48 hours.
Special type of hyponatremia: For syndrome with abnormal secretion of antidiuretic hormone (SIADH), it can inhibit abnormal ADH secretion while promoting water excretion. A study involving 30 patients showed that it can restore normal bleed sodium levels in SIADH patients within 72 hours.
2. Adjuvant treatment for hyperkalemia
When hyperkalemia (blood potassium>5.5mmol/L) occurs, potassium excretion is promoted through the following pathways:
Enhancing renal tubular potassium secretion: By constricting renal bleed vessels, increasing the activation of the renin angiotensin aldosterone system (RAAS), promoting aldosterone secretion, and thereby increasing potassium excretion.
Animal experiments have shown that it can increase urinary potassium excretion by 30% -50%.
Combination therapy: When used in combination with traditional potassium lowering drugs such as insulin, glucose, and salbutamol, it can enhance the therapeutic effect. Clinical studies have shown that the rate of decrease in blood potassium in the combination therapy group is 40% faster than using traditional drugs alone.
Dose limitation: Excessive use should be avoided during hyperkalemia to prevent worsening of hyponatremia. It is recommended that the single dose not exceed 0.5mg and the total daily dose not exceed 1.5mg.
Terlipressin tablet plays an irreplaceable role in various clinical scenarios by precisely regulating fluid distribution and electrolyte balance. The clinical value of alternative treatment for central diabetes insipidus, management of ascites in cirrhosis, fluid resuscitation after burns, and control of cerebral edema has been widely recognized. In the future, with a deeper understanding of the mechanism of action and improvements in drug delivery techniques, the application scope of product will be further expanded, bringing hope for the treatment of more patients with fluid balance disorders.
Hot Tags: terlipressin tablet, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale